TY - JOUR
T1 - Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus
AU - Karmakar, Abhibroto
AU - Kumar, Uma
AU - Prabhu, Smitha
AU - Ravindran, Vinod
AU - Nagaraju, Shankar Prasad
AU - Suryakanth, Varashree Bolar
AU - Prabhu, Mukhyaprana M.
AU - Karmakar, Subhradip
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life. Despite several attempts to comprehend the pathogenesis of SLE, knowledge about the precise molecular mechanisms underlying this disease is still lacking. The current treatment options for SLE are pragmatic and aim to develop composite biomarkers for daily practice, which necessitates the robust development of novel treatment strategies and drugs targeting specific responsive pathways. In this communication, we review and aim to explore emerging therapeutic modalities, including multiomics-based approaches, rational drug design, and CAR-T-cell-based immunotherapy, for the management of SLE.
AB - Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, systemic autoimmune disease characterized by autoantibody production, complement activation, and immune complex deposition. SLE predominantly affects young, middle-aged, and child-bearing women with episodes of flare-up and remission, although it affects males at a much lower frequency (female: male; 7:1 to 15:1). Technological and molecular advancements have helped in patient stratification and improved patient prognosis, morbidity, and treatment regimens overall, impacting quality of life. Despite several attempts to comprehend the pathogenesis of SLE, knowledge about the precise molecular mechanisms underlying this disease is still lacking. The current treatment options for SLE are pragmatic and aim to develop composite biomarkers for daily practice, which necessitates the robust development of novel treatment strategies and drugs targeting specific responsive pathways. In this communication, we review and aim to explore emerging therapeutic modalities, including multiomics-based approaches, rational drug design, and CAR-T-cell-based immunotherapy, for the management of SLE.
UR - http://www.scopus.com/inward/record.url?scp=85204419010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85204419010&partnerID=8YFLogxK
U2 - 10.1007/s10238-024-01484-z
DO - 10.1007/s10238-024-01484-z
M3 - Review article
C2 - 39294397
AN - SCOPUS:85204419010
SN - 1591-8890
VL - 24
JO - Clinical and Experimental Medicine
JF - Clinical and Experimental Medicine
IS - 1
M1 - 223
ER -